Trevi Therapeutics Advances Chronic Cough Pipeline with Phase 3 Trials — Trevi Therapeutics, Inc.

Event summary

Initiated Phase 3 OCEAN-1 trial for IPF-related chronic cough in Q2 2026, with topline data expected in H1 2028.
Phase 3 OCEAN-2 trial expected to initiate in Q3 2026, with topline results anticipated in H2 2027.
Launched Phase 2b LAKE trial for refractory chronic cough in Q2 2026, with sample size re-estimation expected in Q4 2026.
Ended Q2 2026 with $318.9 million in cash, cash equivalents, and marketable securities.

The big picture

Trevi Therapeutics is advancing its pipeline with multiple Phase 3 and Phase 2b trials for chronic cough indications, positioning Haduvio as a potential first-in-class therapy. The company’s strong cash position following its April financing provides a solid foundation to execute on these plans, despite the absence of FDA-approved therapies in this space.

What we're watching

Regulatory Strategy: Whether Trevi can secure FDA alignment on the development plan for non-IPF ILD-related chronic cough.
Clinical Execution: The pace at which Trevi enrolls patients in its Phase 3 and Phase 2b trials, particularly given the competitive landscape.
Financial Runway: How long Trevi’s current cash position will sustain its development plans through potential FDA approval for IPF-related chronic cough.